Á. Artal

12.8k total citations · 1 hit paper
82 papers, 4.3k citations indexed

About

Á. Artal is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Á. Artal has authored 82 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Oncology, 49 papers in Pulmonary and Respiratory Medicine and 14 papers in Molecular Biology. Recurrent topics in Á. Artal's work include Lung Cancer Treatments and Mutations (42 papers), Lung Cancer Research Studies (33 papers) and Lung Cancer Diagnosis and Treatment (18 papers). Á. Artal is often cited by papers focused on Lung Cancer Treatments and Mutations (42 papers), Lung Cancer Research Studies (33 papers) and Lung Cancer Diagnosis and Treatment (18 papers). Á. Artal collaborates with scholars based in Spain, United States and United Kingdom. Á. Artal's co-authors include Achim Rittmeyer, C. Lewanski, Julien Mazières, Johan Vansteenkiste, Daniel Waterkamp, Marcin Kowanetz, Pei He, Louis Fehrenbacher, Jing Yi and Wei Zou and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Á. Artal

77 papers receiving 4.2k citations

Hit Papers

Atezolizumab versus docetaxel for patients with previousl... 2016 2026 2019 2022 2016 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
    2016 2.1k citations Louis Fehrenbacher, Johan Vansteenkiste et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Á. Artal Spain 20 3.2k 2.5k 878 607 606 82 4.3k
Matthew A. Gubens United States 30 3.4k 1.1× 2.3k 0.9× 565 0.6× 754 1.2× 524 0.9× 100 4.3k
Kun He United States 27 2.0k 0.6× 1.3k 0.5× 835 1.0× 578 1.0× 475 0.8× 53 3.2k
Anna Spreafico Canada 31 2.3k 0.7× 1.2k 0.5× 1.2k 1.4× 567 0.9× 591 1.0× 229 3.8k
Kathryn C. Arbour United States 21 2.5k 0.8× 1.8k 0.7× 1.3k 1.5× 448 0.7× 747 1.2× 53 3.8k
Mitsuhiro Takenoyama Japan 36 2.2k 0.7× 1.9k 0.8× 965 1.1× 1.1k 1.8× 374 0.6× 221 3.9k
Achim Rittmeyer United States 26 4.9k 1.6× 3.5k 1.4× 593 0.7× 1.1k 1.8× 687 1.1× 91 5.7k
Mengzhao Wang China 31 2.4k 0.8× 2.5k 1.0× 973 1.1× 247 0.4× 658 1.1× 229 3.9k
William J. John United States 29 3.0k 0.9× 2.9k 1.2× 972 1.1× 384 0.6× 585 1.0× 84 4.5k
Wenfeng Fang China 33 3.4k 1.1× 2.4k 1.0× 1.1k 1.2× 681 1.1× 890 1.5× 201 4.9k
Shunichi Sugawara Japan 36 4.2k 1.3× 3.5k 1.4× 1.1k 1.2× 448 0.7× 548 0.9× 209 5.4k

Countries citing papers authored by Á. Artal

Since Specialization
Citations

This map shows the geographic impact of Á. Artal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Á. Artal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Á. Artal more than expected).

Fields of papers citing papers by Á. Artal

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Á. Artal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Á. Artal. The network helps show where Á. Artal may publish in the future.

Co-authorship network of co-authors of Á. Artal

This figure shows the co-authorship network connecting the top 25 collaborators of Á. Artal. A scholar is included among the top collaborators of Á. Artal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Á. Artal. Á. Artal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Artal, Á., et al.. (2024). Lung immune prognostic index (LIPI) as a prognostic factor in patients with extensive-stage small cell lung cancer treated with first-line chemoimmunotherapy. Clinical & Translational Oncology. 27(4). 1484–1492. 1 indexed citations
2.
Alcorn, Sara R., Á. Artal, Lisa Bradfield, et al.. (2024). External Beam Radiation Therapy for Palliation of Symptomatic Bone Metastases: An ASTRO Clinical Practice Guideline. Practical Radiation Oncology. 14(5). 377–397. 21 indexed citations
3.
Garrido, Pilar, Luis Paz‐Ares, Margarita Majem, et al.. (2021). LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology. Cancer Medicine. 10(17). 5878–5888. 14 indexed citations
4.
5.
Arriola, Edurne, Ramón García Gómez, Pilar Díz, et al.. (2018). Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain. BMC Cancer. 18(1). 106–106. 14 indexed citations
6.
Remón, Jordi, Dolores Isla, Pilar Garrido, et al.. (2017). Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database. Clinical & Translational Oncology. 19(12). 1537–1542. 4 indexed citations
7.
Garrido, Pilar, Marcelo Sánchez, Nicolás Moreno‐Mata, et al.. (2017). Reflexiones sobre la implementación del cribado mediante tomografía computarizada de baja dosis en personas con riesgo elevado de padecer cáncer de pulmón en España. Archivos de Bronconeumología. 53(10). 568–573. 11 indexed citations
8.
Rittmeyer, Achim, David C. Smith, Johan Vansteenkiste, et al.. (2017). Updated survival and biomarker analyses of a randomized phase II study of atezolizumab vs. docetaxel in 2L/3L NSCLC (POPLAR). Pneumologie. 71(S 01). S1–S125. 4 indexed citations
9.
Ascaso, Francisco J., et al.. (2009). Bilateral Choroidal Metastases Revealing an Advanced Non-Small Cell Lung Cancer. The Annals of Thoracic Surgery. 88(3). 1013–1015. 14 indexed citations
10.
Martínez‐Trufero, Javier, Juan Lao, Teresa Puértolas, et al.. (2005). Serum Markers and Prognosis in Locally Advanced Breast Cancer. Tumori Journal. 91(6). 522–530. 15 indexed citations
11.
Camps, Carlos, Enriqueta Felip, José Miguel Sánchez, et al.. (2005). Phase II trial of the novel taxane BMS-184476 as second-line in non-small-cell lung cancer. Annals of Oncology. 16(4). 597–601. 21 indexed citations
12.
Isla, Dolores, Carme Sarries, Rafael Rosell, et al.. (2004). Single nucleotide polymorphisms and outcome in docetaxel–cisplatin-treated advanced non-small-cell lung cancer. Annals of Oncology. 15(8). 1194–1203. 255 indexed citations
13.
Maurel, Joan, Teresa Puértolas, Antonio Antón, et al.. (2001). Phase I trial of weekly gemcitabine at 3-h infusion in refractory, heavily pretreated advanced solid tumors. Anti-Cancer Drugs. 12(9). 713–717. 20 indexed citations
14.
15.
16.
Antón, A., J.L. González-Larriba, Catalina Vadell, et al.. (1998). Phase II trial assessing the combination of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC). Lung Cancer. 22(2). 139–148. 35 indexed citations
17.
Artal, Á., et al.. (1992). [Autoimmune hemolytic anemia and carcinoma of the larynx: an exceptional association].. PubMed. 191(4). 207–8. 2 indexed citations
18.
Feliú, Jaime, M. González‐Barón, Á. Artal, et al.. (1992). Usefulness of Megestrol Acetate in Cancer Cachexia and Anorexia. American Journal of Clinical Oncology. 15(5). 436–440. 80 indexed citations
19.
Artal, Á., et al.. (1991). [Descriptive study of the care of oncologic patients at the emergency service of a general hospital].. PubMed. 188(7). 345–8. 2 indexed citations
20.
Barón, Manuel González, José Ignacio Chacón, Carlos García Girón, et al.. (1991). Antiemetic Regimens in Outpatients Receiving Cisplatin and Non-Cisplatin Chemotherapy: A Randomized Trial Comparing High-Dose Metoclopramide Plus Methylprednisolone with and Without Lorazepam. Acta Oncologica. 30(5). 623–627. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Matthew A. Gubens Breakdown of academic impact, for papers by Kun He Breakdown of academic impact, for papers by Anna Spreafico Breakdown of academic impact, for papers by Kathryn C. Arbour Breakdown of academic impact, for papers by Mitsuhiro Takenoyama Breakdown of academic impact, for papers by Achim Rittmeyer Breakdown of academic impact, for papers by Mengzhao Wang Breakdown of academic impact, for papers by William J. John Breakdown of academic impact, for papers by Wenfeng Fang Breakdown of academic impact, for papers by Shunichi Sugawara
Rankless by CCL
2026